PNPLA3 and metabolic dysfunction-associated steatotic liver disease: However, it remains unclear whether AMPK activation decreases PNPLA3 expression in the liver and prevents NAFLD and whether the decreased binding energy of bioactive compounds with PNPLA3 reduces its expression to reduce hepatic lipogenesis.